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Malignant glaucoma is a rare form of glaucoma that typically follows surgery in patients with primary angle closure and primary
angle-closure glaucoma. In this paper, the clinical features, classiﬁcation, pathogenesis, and principles of management are dis-
cussed. Despite a high prevalence of primary angle closure glaucoma in South-East Asia, the vast majority of cases of malignant
glaucoma are reported in White populations. This may reﬂect diﬀering mechanisms of angle closure in White and Asian patients,
which somehow reduces the likelihood of an aberrant relationship developing between the lens, ciliary body, anterior hyaloid, and
vitreous structures within the eye. Although the exact underlying pathogenic mechanism remains unclear, the prognosis is good
with modern medical, laser, and surgical treatment modalities.
1.Introduction
The term “malignant glaucoma” was coined by von Graefe
in 1869 to describe an aggressive form of postoperative glau-
coma that was resistant to treatment and resulted in blind-
ness [1]. It is alternatively known by names relating to the
proposed pathogenic mechanisms of this condition, such as
ciliaryblock glaucoma,aqueousmisdirection syndrome, and
direct lens-block glaucoma [2–4]. It should be emphasised
to patients with malignant glaucoma that the term does not
indicate a neoplastic process, that glaucomatous damage to
the optic disc is not always a consequence of the condition,
andthattheprognosisisgoodwithmodernlaserandsurgical
approaches to management.
2.Why IsMalignantGlaucomaSoRare?
Classical malignant glaucoma is reported to occur in 0.4–6%
cases of incisional surgery for primary angle-closure glau-
coma [5–7]. Most case series of malignant glaucoma report
this as a consequence of surgery in White patients with
primary angle closure or primary angle-closure glaucoma.
Since primary angle-closure glaucoma is a particularly com-
mon form of glaucoma in South-East Asia and China, it
is remarkable that malignant glaucoma is not described as
a complication of surgery in these patients with primary
angle-closure glaucoma [8–11]. This may reﬂect a diﬀerent
aetiology and physiologic basis of angle closure in White and
Asian subjects; a subject that has not yet been resolved [12].
Where malignant glaucoma occurs in nonsurgical situa-
tions or spontaneously, the literature contains isolated case
reports and the absence of large case series of such occur-
rences underlines the rarity of this condition.
3. What Arethe ClinicalFeaturesof
MalignantGlaucoma?
Malignant glaucoma is diagnosed when there is shallowing
of the central (axial) anterior chamber in association with
increased intraocular pressure (IOP) and normal posterior
segment anatomy. Absence of pupillary block needs to be
conﬁrmed by the presence of a patent iridotomy and pos-
teriorsegmentpathology(particularlysuprachoroidalhaem-
orrhage) should be excluded through careful fundus evalua-
tion.
The ﬁrst symptom is often an improvement in near
vision secondary to a myopic shift in refraction as the lens-
iris diaphragm moves forward. Malignant glaucoma can be
diﬃcult to detect early in its course before elevation in
IOP occurs. In most eyes the IOP is typically greater than2 Journal of Ophthalmology
21mmHg, but in some eyes the IOP may be normal or even
low [13]. Pain and inﬂammation occurs when the intraoc-
ular pressure rises spontaneously and corneal oedema may
develop. There is an absence of forward bowing of the iris.
Ultrasound biomicroscopy (UBM) of eyes during an
episode of malignant glaucoma shows anterior rotation of
the ciliary processes, which press against the lens equator (or
the anterior hyaloid in aphakia) and prevent forward ﬂow
of aqueous (hence the term ciliary block glaucoma) [13–
15]. It is possible that malignant glaucoma is part of a spec-
trumofdisordersassociatedwithasmallidiopathic supracil-
iary eﬀusion that is partially responsible for anterior ciliary
body rotation, aqueous misdirection, and anterior segment
structure displacement [14]. UBM also shows that the size
of the lens in some eyes with malignant glaucoma is smaller
than normal, and this may allow the lens to move forward
within the eye [16].
4.How CanMalignantGlaucomaBe Classiﬁed?
Malignant glaucoma may be classiﬁed as classic malignant
glaucoma, nonphakic glaucoma, and other malignant glau-
coma syndromes [17, 18].
(a) Classic malignant glaucoma is a rare complication
of incisional surgery for primary angle-closure glau-
coma [5, 6]. It can occur in phakic, aphakic, and
pseudophakic eyes, and its occurrence appears to be
independent of the type of surgery and the preop-
erative intraocular pressure level prior to surgery.
The timing is variable, ranging from the immediate
postoperative period to many years after surgery and
may coincide with the cessation of cycloplegic drugs
[19–21]. Partial or total closure of the drainage angle
at the time of surgery and axial hypermetropia is
associated with an increased risk [5, 22].
(b) Nonphakic malignant glaucoma develops in patients
after cataract extraction. This group of patients in-
cludes those in whom there is persistent malignant
glaucoma despite cataract extraction. It can occur in
eyes with or without glaucoma [5, 23].
(c) Other malignant glaucoma syndromes; although
usually associated with ﬁltration surgery, malignant
glaucoma may occur spontaneously [24, 25] and has
also been described in a number of glaucoma-related
situations. These include laser treatment (peripheral
laser iridotomy [26, 27], trabeculectomy scleral ﬂap
suture lysis [28, 29], and cyclophotocoagulation
[30]);useofmiotics[31,32]andtrabeculectomybleb
needling [33]. There are sporadic reports of malig-
nant glaucoma in association with infection [34, 35],
retinopathy of prematurity [36, 37], retinal detach-
ment [38], retinal vein occlusion [39], and trauma
[40]. It is plausible that malignant glaucoma may
arise in some of these situations following ciliary
body swelling and the formation of an inﬂammatory
barrier in the zonular-capsular region which impedes
a n t e r i o rﬂ o wo fa q u e o u sh u m o u r[ 41]. However,
some isolated reports may simply represent misdiag-
nosis, as the mechanism of precipitating the episode
of malignant glaucoma in these circumstances is
unclear.
5.What Is the Pathogenic Mechanism
UnderlyingMalignant Glaucoma?
Malignant glaucoma is a multifactorial condition that is
thought to occur in anatomically predisposed eyes. Although
poorlyunderstood,thepathophysiologyisthoughttoinvolve
an alteration in the anatomic relationship of the lens, ciliary
body, anterior hyaloid face, and vitreous, which results in
forward movement of the iris-lens diaphragm. While the
exact mechanism remains unclear, three pathogenic mech-
anisms have been proposed.
(a) Shaﬀer and Hoskins suggested that posterior diver-
sion of aqueous ﬂow causes accumulation of aqueous
behind a posterior vitreous detachment with sec-
ondaryforwardmovementoftheiris-lensdiaphragm
[42]. He and Hoskins observed collections of ﬂuid
behind the vitreous gel, which also seemed more
dense than normal, and believed that this prevented
forward ﬂow of aqueous [2]. Shaﬀer and Hoskins
postulated a valve-like mechanism by which aqueous
humour was “misdirected” posteriorly. The mecha-
nism causing the posterior diversion of aqueous and
the nature of the unidirectional valve remain unclear.
(b) Chandlerproposedthatlaxityoflenszonulescoupled
with pressure from the vitreous leads to forward lens
movement.Aviciouscircleissetupinthatthehigher
thepressureintheposteriorsegment,themoreﬁrmly
the lens is held forward [6].
(c) Quigley et al. proposed that the precipitating event
which increases vitreous pressure is choroidal expan-
sion [43, 44] and that the initial compensatory out-
ﬂow of aqueous along the posteroanterior pressure
gradient causes shallowing of the anterior chamber.
Choroidal expansion has been detected on UBM in
eyes with malignant glaucoma, and choroidal eﬀu-
sion secondary to angio-oedema has also been re-
ported to result in malignant glaucoma [45, 46].
Whatever the mechanism, the ﬁnal common pathway is the
establishment of a vicious cycle whereby the transvitreal
pressure cannot be equalised by outﬂow of aqueous humour.
As the pressure rises, the anterior vitreous gel becomes less
permeable to the forward movement of gel and this exacer-
bates the problem [47]. Fluid buildup behind the vitreous
leads to vitreous condensation which exerts a forward force,
resultinginanteriordisplacementofthelens-irisdiaphragm.
In small eyes prone to angle closure the forward movement
would look like acute pupillary block. However, iridotomy
does not reverse the situation. The concept that the lens
subsequently pushes the peripheral iris into the anterior
chamber angle led to the proposed term of “direct lens block
glaucoma” [6].Journal of Ophthalmology 3
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Figure 1: Management pathway for malignant glaucoma.
6.What Arethe Principlesof
Management of Malignant Glaucoma?
Theﬁrststepistomakeanaccuratediagnosisandexcludethe
diﬀerential diagnoses of pupillary block glaucoma, a supra-
choroidal haemorrhage or choroidal eﬀusion and secondary
causes of angle closure. Once the diagnosis is made, the fol-
lowing pathway of management can be followed (Figure 1).
6.1. Medical Therapy
6.1.1. Cycloplegia. Mydriatics (atropine and phenylephrine)
should be given immediately in order to tighten the lens
zonules and pull the anteriorly displaced lens backwards
[5,40].Thiscondition does notrespond totheuseofmiotics
(unlike pupillary block), which are contraindicated as they
may exacerbate the situation by promoting zonular relax-
ation and encourage forward lens movement.
6.1.2. Intraocular Pressure Reduction. Oral acetazolamide
and topical beta-blockers and alpha agonists are used to re-
duce aqueous production.
6.1.3. Reduction of Vitreous Volume. Osmotic agents (man-
nitol or glycerol) are used to reduce vitreous volume,
deepen the anterior chamber, and possibly increase vitreous
permeability [48].
6.1.4. Anti-Inﬂammatory Medication. Topical steroids can
help to reduce inﬂammation [49]. Medical management is
reportedtobecurativein50%patientswithina5-dayperiod
[5]. Once the anterior chamber deepens and the IOP nor-
malises, medical treatment can be slowly withdrawn, with
the osmotic agent stopped ﬁrst, then the aqueous sup-
pressants and ﬁnally the cycloplegic medication. Indeﬁnite
cycloplegia with topical atropine or other cycloplegics may
be required to prevent recurrence [50].
6.2. Laser Therapy. Successful laser treatment aims to restore
a normal aqueous ﬂow pattern by establishing a direct com-
munication between the vitreous cavity and anterior cham-
ber.
6.2.1. Disruption of Anterior Hyaloid Face. An intact hyaloid
face is an important pathogenic factor in malignant glau-
comaandinpseudophakicoraphakicpatients,Nd:YAGlaser
capsulotomy with disruption of the anterior hyaloid face is
ofteneﬀective[15,51–53].UBMimagingshowsthatanterior
rotation of the ciliary body and anterior chamber shallowing
normalise after rupture of the anterior hyaloid face [15]. It
hasbeensuggestedthatalargeopticlens(greaterthan7mm)
orthepresenceofsynechiaebetweentheimplantandcapsule
maypreventsubsequentﬂowofaqueousforwardsandinthis
situation laser capsulotomy can be performed in the region
of the lens dialling hole (if present) to allow direct passage of
aqueous into the anterior chamber [54].
6.2.2. Laser of Ciliary Processes. The successful use of transs-
cleral cyclodiode laser photocoagulation in pseudophakic
patients can help eliminate an abnormal vitreociliary rela-
tionship by posterior rotation of the ciliary processes sec-
ondary to coagulative shrinkage [55, 56]. Often a single
session of therapy is suﬃcient over 1-2 quadrants [56]. An
alternative option is direct argon laser treatment of the
ciliary processes through a peripheral iridotomy [57]. Cyclo-
cryotherapy has been used in the past but no longer has a
place in modern management [58].4 Journal of Ophthalmology
6.3. Surgical Therapy. In malignant glaucoma that is refrac-
tory to medical and laser therapy, surgical intervention to
remove the vitreous is necessary to increase aqueous ﬂow
into the anterior chamber [50, 59]. The success of this was
ﬁrst described by Chandler, who reported a method of vit-
reous aspiration through an 18-guage needle via an incision
throughtheparsplana[60].Withtime,thisprincipleofther-
apy has evolved into current pars plana vitrectomy surgery
techniques.
The key role of removal of the anterior vitreous is
demonstrated by the fact that core vitrectomy surgery leads
to resolution of malignant glaucoma in only 25–50% of the
phakic eyes compared to 65–90% pseudophakic eyes [13, 61,
62]. This probably reﬂects the lack of eﬀective removal of
the anterior hyaloid in phakic eyes because of the risk of
lensdamageandsubsequentcataractformation.Atechnique
of intraocular videoendoscope-guided, ﬂuorescein-assisted
pars plana vitrectomy that allows direct visualisation and
thorough removal of the anterior vitreous without the need
for lens extraction in prepresbyopic patients has been suc-
cessfully used in malignant glaucoma [63].
Intracapsular cataract extraction has been reported to be
successful in 50% cases [61]. Combined cataract extraction
and vitrectomy in phakic eyes can increase the success rate
from 25% to 83% if the posterior capsule is removed [62].
Thekeyfeatureisthattheposteriorcapsulemustbebreached
and the anterior vitreous removed, so that the relationship
between the vitreous and ciliary body that predisposes to the
vicious cycle of malignant glaucoma is disrupted. Therefore,
in phakic patients, deﬁnitive management requires pha-
coemulsiﬁcation surgery plus intraocular lens implantation
combined with removal of the posterior capsule at time of
vitrectomy [49, 60, 61]. A staged surgical approach may help
overcometechnicaldiﬃcultieswithphacoemulsiﬁcationsur-
gery in the presence of a shallow anterior chamber and high
intraocular pressure. A preliminary core vitrectomy is ini-
tially done to debulk the vitreous, soften the eye, and deepen
the anterior chamber, followed by standard phacoemulsi-
ﬁcation surgery and intraocular lens implantation. Finally,
residual vitrectomy and hyaloidectomy with removal of
the retrolental posterior capsule are performed [64]. Some
authorsadvocate the additional stepofzonulohyaloidectomy
[65]. In resistant cases, pars plana glaucoma tube insertion
has been described [66].
Since malignant glaucoma often follows trabeculectomy
surgery, there is a risk of long-term failure of the ﬁltration
bleb as a consequence of any additional surgical procedures
needed to treat malignant glaucoma. Byrnes et al. recorded
bleb failure in 16% eyes following pars plana vitrectomy
[61]. Careful followup is needed to monitor this, so that
appropriate intervention can be instituted if needed.
6.4.ManagementoftheFellowEye. Afteranepisodeofmalig-
nant glaucoma in one eye, there is a high risk of this com-
plication occurring in the fellow eye after a surgical interven-
tion[67].Thepatientshouldbewarnedofthiswhenconsent
is taken for surgery on the fellow eye. Prophylactic measures
include cessation of miotic drops (which cause ciliary body
swelling and anterior rotation of the lens-iris diaphragm),
prolongeduseofatropineaftertrabeculectomysurgery(with
careful monitoring after this is stopped), and avoidance of
anterior chamber shallowing in the postoperative period
(using anterior chamber viscoelastic and tight scleral ﬂap
suturing). Preoperatively, a prophylactic laser peripheral
iridotomy is recommended by some (although this can itself
occasionally lead to malignant glaucoma) [23]. These meth-
ods will help maintain the normal anatomical position of
the iris-lens diaphragm and reduce the risk of aqueous mis-
direction.
In eyes with primary angle-closure glaucoma that is not
medically controlled, lens extraction may be undertaken as
a primary procedure, rather than ﬁltration surgery [9]. The
former has a lower risk of malignant glaucoma and, if it
occurs, the management is easier in a pseudophakic eye.
Some specialists have advocated prophylactic pars plana vit-
rectomy at the time of phacoemulsiﬁcation with intraocular
lens implantation to prevent malignant glaucoma in high-
risk fellow eyes [68].
7. Conclusion
Malignant glaucoma continues to provide a therapeutic
challenge, which probably reﬂects our limited understanding
of its aetiology. It is curious that this condition appears to be
extremely rare in Asians, where the prevalence of primary
angle-closure glaucoma is common. Whatever the true
mechanism, the fact that it is relieved when a direct com-
munication is made between the anterior chamber and
vitreous cavity supports the theory that the lens, anterior
vitreous, and ciliary processes are intimately involved in the
pathogenesis. The fact that it often occurs in fellow eyes
suggests that it is a tendency in an individual rather than a
ra n d o mev e n t .A lley e swi t hp ri m a rya n gl e - c l o s u r egl a u c o m a
should be closely followed, particularly in the early post-
operative period following glaucoma drainage surgery. If a
patient develops malignant glaucoma in one eye, preventive
measuresshouldbetakentopreventitoccurringinthefellow
eye at the time of surgery. The prognosis of this condition
is good with currently available treatment modalities and
malignant glaucoma no longer deserves its historical name.
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